Delivering on HopeTM

NBI-1065846

NBI-1065846 (TAK-041) is being developed by Neurocrine Biosciences and Takeda Pharmaceutical Company Limited as part of a strategic collaboration announced in June 2020. The compound is a potential first-in-class GPR139 agonist for the treatment of anhedonia in depression. NBI-1065846 has completed multiple Phase I studies in healthy participants and preparations are underway for a Phase II studies in adult patients.